http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2446821-C2
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_86de7d9f2e6454d7c2f6aeaf3b9541b6 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 |
filingDate | 2010-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2012-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9476298fe8fa312832665179e9181cf6 |
publicationDate | 2012-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | RU-2446821-C2 |
titleOfInvention | Drug preparation for treating infectious diseases accompanied by neurotoxic disorders, and method of treating infectious diseases accompanied by neurotoxic disorders |
abstract | FIELD: medicine, pharmaceutics. n SUBSTANCE: drug preparation for treating infectious diseases accompanied by neurotoxic disorders including neuroinfectious and neurodegenerative diseases is presented in the form of a pharmaceutical composition and contains an activated potentiated form of human gamma interferon (IFN-γ) antibodies and an activated potentiated form of brain-specific S-100 antibodies. The pharmaceutical composition is presented in a solid dosage form - in the form of granules. As pharmaceutically acceptable additives, it contains lactose, microcrystalline cellulose and magnesium stearate, and each of the components of very-low-dose affinity purified antibodies are used in the form of a mixture of various, preferentially homoeopathic dilutions 1/100. A method of treating and preventing infectious diseases accompanied by neurotoxic disorders involves the introduction into a body of the activated potentiated form of IFN-γ antibodies, and an enhancing agent in the form of the activated potentiated form of very-low-dose affinity purified brain-specific S-100 antibodies. n EFFECT: use of the invention enables enhanced immune response at height of the disease, ensures effective rehabilitation and prevents recurrences of the disease. n 14 cl, 4 dwg, 1 tbl, 2 ex |
priorityDate | 2010-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 650.